These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28819782)

  • 1. The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.
    Jafarnezhad-Ansariha F; Yekaninejad MS; Jamshidi AR; Mansouri R; Vojdanian M; Mahmoudi M; Fattahi MJ; Hashemi SN; Rehm BHA; Matsuo H; Esposito E; Cuzzocrea S; Mirshafiey A
    Inflammopharmacology; 2018 Apr; 26(2):375-384. PubMed ID: 28819782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial.
    Fattahi MJ; Jamshidi AR; Mahmoudi M; Vojdanian M; Yekaninejad MS; Jafarnezhad-Ansariha F; Ahmadi H; Rehm BHA; Matsuo H; Cuzzocrea S; Hosseini M; Hashemi SN; Aghazadeh Z; Mirshafiey A
    Int Immunopharmacol; 2018 Jan; 54():112-117. PubMed ID: 29127910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression.
    Mirshafiey A; Taeb M; Mortazavi-Jahromi SS; Jafarnezhad-Ansariha F; Rehm BHA; Esposito E; Cuzzocrea S; Matsuo H
    Pharmacol Rep; 2017 Oct; 69(5):1067-1072. PubMed ID: 28951072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potent suppressive effect of β-d-mannuronic acid (M2000) on molecular expression of the TLR/NF-kB Signaling Pathway in ankylosing spondylitis patients.
    Roozbehkia M; Mahmoudi M; Aletaha S; Rezaei N; Fattahi MJ; Jafarnezhad-Ansariha F; Barati A; Mirshafiey A
    Int Immunopharmacol; 2017 Nov; 52():191-196. PubMed ID: 28938189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis.
    Fattahi MJ; Ahmadi H; Jafarnezhad-Ansariha F; Mortazavi-Jahromi SS; Rehm BHA; Cuzzocrea S; Matsuo H; Mirshafiey A
    Biomed Pharmacother; 2018 Apr; 100():495-500. PubMed ID: 29477913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients.
    Gaafar NAG; Aslani M; Aghazadeh Z; Razavi A; Mirshafiey A
    Curr Drug Discov Technol; 2020; 17(5):704-710. PubMed ID: 31250758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (β-D-mannuronic Acid) as a Novel NSAID with Immunosuppressive Property.
    Jahanbakhshi M; Babaloo Z; Mortazavi-Jahromi SS; Shokri MM; Ahmadi H; Mirshafiey A
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):530-536. PubMed ID: 29667557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules NFκB, IL-8 and Cd49d using Healthy Donor PBMC.
    Khalatbari A; Mahdavi M; Jafarnezhad F; Afraei S; Zavareh FT; Aghazadeh Z; Ghaderi A; Mirshafiey A
    Curr Drug Discov Technol; 2020; 17(2):225-232. PubMed ID: 30417790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of β-d-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on
    Barati A; Jamshidi AR; Ahmadi H; Aghazadeh Z; Mirshafiey A
    Drug Des Devel Ther; 2017; 11():1027-1033. PubMed ID: 28408801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological Improvement of Patients with Active Rheumatoid Arthritis by β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property.
    Ahmadi H; Jamshidi AR; Mahmoudi M; Gharibdoost F; Vojdanian M; Fattahi MJ; Rastkari N; Aghazadeh Z; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2017 Oct; 16(5):433-442. PubMed ID: 29149783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Anti-tumoral Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID on Treg Cells Frequency and MMP-2, MMP-9, CCL22 and TGFβ1 Gene Expression in Pre-surgical Breast Cancer Patients.
    Kashefi S; Ahmadi H; Omranipour R; Mahmoodzadeh H; Jafarnezhad-Ansariha F; Tofighi Zavareh F; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2019 Feb; 18(1):80-90. PubMed ID: 30848576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-aging effects of M2000 (β-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model.
    Hosseini S; Abdollahi M; Azizi G; Fattahi MJ; Rastkari N; Zavareh FT; Aghazadeh Z; Mirshafiey A
    J Basic Clin Physiol Pharmacol; 2017 May; 28(3):249-255. PubMed ID: 28207414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Anti-Migraine Effects of M2000 (β-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis: Case Report.
    Vojdanian M; Ahmadi H; Jamshidi AR; Mahmoudi M; Gharibdoost F; Barati A; Mirshafiey A
    Curr Clin Pharmacol; 2017; 12(2):127-130. PubMed ID: 28578645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological effects of β-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions.
    Mortazavi-Jahromi SS; Jamshidi MM; Farazmand A; Aghazadeh Z; Yousefi M; Mirshafiey A
    Pharmacol Rep; 2017 Jun; 69(3):479-484. PubMed ID: 28324845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis.
    Ahmadi H; Jamshidi AR; Mahmoudi M; Cuzzocrea S; Fattahi MJ; Barati A; Rehm BHA; Matsuo H; Mirshafiey A
    Curr Drug Discov Technol; 2017; 14(3):206-214. PubMed ID: 28325148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of β-d-mannuronic acid, as a new non-steroidal anti-inflammatory drug on expression of miR-146a, IRAK1, TRAF6, NF-κB and pro-inflammatory cytokines following a clinical trial in rheumatoid arthritis patients.
    Mortazavi-Jahromi SS; Ahmadzadeh A; Rezaieyazdi Z; Aslani M; Omidian S; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2020 Jun; 42(3):228-236. PubMed ID: 32223462
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the oral administration of α-l-guluronic acid on COX-1 and COX-2 gene expression profile in ankylosing spondylitis patients.
    Sadoughi A; Mansouri R; Nazeri S; Mirshafiey A
    Drug Dev Res; 2021 Apr; 82(2):296-301. PubMed ID: 33140463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Effect of Mannuronic Acid as a Novel NSAID With Immunosuppressive Properties on Expression of SOCS1, SOCS3, SHIP1, and TRAF6 Genes and Serum Levels of IL-6 and TNF-α in Patients With Multiple Sclerosis.
    Najafi S; Saadat P; Beladi Moghadam N; Manoucherinia A; Aghazadeh Z; Vali Mohammadi A; Pashaiefar H; Hosseini M; Mirshafiey A
    J Clin Pharmacol; 2021 Oct; 61(10):1303-1310. PubMed ID: 33908653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial.
    Nazeri S; Jamshidi AR; Mahmoudi M; Vojdanian M; Khadem Azarian S; Afraei S; Mostafaei S; Hosseini M; Mirshafiey A
    Pharmacol Rep; 2019 Jun; 71(3):393-398. PubMed ID: 31003148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-D-mannuronic acid in rheumatoid arthritis patients.
    Ahmadi H; Jamshidi AR; Gharibdoost F; Mahmoudi M; Rastkari N; Mostafaei S; Fattahi MJ; Vojdanian M; Cuzzocrea S; Rehm BHA; Matsuo H; Hosseini M; Aghazadeh Z; Mortazavi-Jahromi SS; Mirshafiey A
    Inflammopharmacology; 2018 Jun; 26(3):737-745. PubMed ID: 29696564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.